Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604160 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3113593 in Participants With Chronic Kidney Disease
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02604160 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants.
The verdict
NCT02604160, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body. The study consists of up to three parts. Participants may only enroll in one part. Participants will receive up to four injections of LY3113593 or placebo into a vein. The study will last up to about 26 weeks including screening and follow-up.
Interventions
- DRUG Placebo
- DRUG LY3113593
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-11-17 |
| Est. Completion | 2016-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02604160
The ClinicalTrials.gov registry entry for NCT02604160 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02604160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02604160 about?
NCT02604160 is a clinical study titled "A Study of LY3113593 in Participants With Chronic Kidney Disease". This study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has ...
What is the current status of trial NCT02604160?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-11-17. Estimated completion is 2016-06-22.
What interventions are being tested in trial NCT02604160?
The interventions under investigation include: Placebo (DRUG), LY3113593 (DRUG).
Who is sponsoring clinical trial NCT02604160?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.